恒瑞医药：子公司SHR-1905注射液临床试验获批

Core Viewpoint - Heng Rui Medicine announced the approval of clinical trials for SHR-1905 injection by the National Medical Products Administration, indicating a significant step in the development of a new therapeutic option targeting inflammation [1] Group 1: Company Developments - The subsidiary Guangdong Heng Rui Medicine Co., Ltd. received the clinical trial approval notice for SHR-1905 injection [1] - SHR-1905 is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), which plays a role in blocking the release of inflammatory cytokines [1] Group 2: Product Information - SHR-1905 injection aims to inhibit downstream inflammatory signaling pathways, ultimately improving inflammatory conditions and controlling disease progression [1]